Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 22 of its QS-B220 desktop trace detectors to international airports in Austria , continuing its sales success in the European aviation market.
With this contract win, international airports in 11 EU countries have selected Implant Sciences' QS-B220 since late April 2015 , with orders totaling up to 883 units to such airports.
"When it comes to security, airport operators and security managers are looking for solutions that are easy to own and operate, while providing optimal security for the traveling public. Our systems feature push-button maintenance and an intuitive operating process," stated Dr. Darryl Jones , Implant Sciences' Vice President of Global Sales and Marketing. "The intuitive nature of the QS-B220 allows the security personnel to focus their attention on security, rather than on navigating the interface of the screening equipment. Our low false alarm rate means fewer passengers being unnecessarily inconvenienced which streamlines the checkpoint passenger flow and also provides a superior screening experience for passengers."
"Implant Sciences' cutting-edge ETD technology has a much broader impact than simply having the most sophisticated software, the largest touch-screen, or having the lowest false alarm rate. The impact of the technology is in real terms: fewer passengers stopped unnecessarily, less money spent on consumables, and fewer user errors in operating the system," added Dr. Bill McGann , Implant Sciences' CEO. "Our mission, as the global non-rad ETD experts, is to continue to provide the best technology to meet and exceed the operational needs of our customers."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source: Implant Sciences
Date: Aug 25, 2015